Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 30 2025
0mins
Source: Benzinga
UiPath Financial Results: UiPath Inc. shares surged 13.2% in pre-market trading after reporting first-quarter earnings of 11 cents per share, exceeding analyst expectations, and raising its FY26 guidance with sales of $356.62 million.
Market Movements: Several stocks experienced significant pre-market trading changes, with Bolt Projects Holdings rising 93.4% and Shineco, Inc. falling 49.9%, while The Gap, Inc. dipped 13.7% following a warning about potential tariff costs.
Analyst Views on BLRX
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.880
Low
12.00
Averages
12.00
High
12.00
Current: 2.880
Low
12.00
Averages
12.00
High
12.00
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
